US Patent 7235627 Derivatives of GLP-1 analogs

Is a

Patent

Patent attributes

Current Assignee

Novo Nordisk

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7235627

Date of Patent

June 26, 2007

Patent Application Number

10285079

Date Filed

August 19, 2002

Patent Citations Received

‌

US Patent 12102663 Treatment of post-bariatric hypoglycemia with exendin (9-39)

‌

US Patent 11833248 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

‌

US Patent 11840559 Glucagon-receptor selective polypeptides and methods of use thereof

‌

US Patent 11884713 Acylated glucagon analogues

‌

US Patent 11654183 Methods comprising continuous administration of exenatide and co-administration of a drug

‌

US Patent 11752198 GLP-1 compositions and uses thereof

‌

US Patent 11759503 Compositions of GLP-1 peptides and preparation thereof

‌

US Patent 11759502 Compositions of GLP-1 peptides and preparation thereof

...

Patent Primary Examiner

‌

David Lukton

Patent abstract

The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 7235627 Derivatives of GLP-1 analogs

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 7235627 Derivatives of GLP-1 analogs